How a small molecule promotes removal of excess cholesterol

28-Nov-2018 - Scientists have determined the structure of the activated form of an enzyme that helps to return excess cholesterol to the liver. The research reveals how a drug-like chemical stimulates the action of the lecithin:cholesterol acyltransferase (LCAT) enzyme. It also suggests that future drugs using ...

Snake venom treatment investigated as antibiotic alternative for eye infections

20-Jul-2018 - An innovative University of Liverpool research project that will investigate whether compounds used to treat snake venom and bee stings could provide an alternative to antibiotics in treating eye infection has been awarded £170,000 by the charity Fight for Sight. Professor Stephen Kaye and his ...

Santhera Announces Intent To File Marketing Authorization Application for Leber's Hereditary Optic Neuropathy

23-Sep-2010 - Santhera Pharmaceuticals announced that it has formally notified the European Medicines Agency of its intent to file for Leber's Hereditary Optic Neuropathy (LHON). In the recent RHODOS study, Catena® showed consistent superiority over placebo and, in particular, improved or protected visual ...

ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for Vitreomacular Adhesion

Highly significant trial result (p=0.003) demonstrates the potential of microplasmin in the treatment of retinal disease

21-Apr-2010 - ThromboGenics NV announced that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint (p=0.003). The trial, TG-MV-006, recruited a total of 326 patients in the U.S. A second Phase III study with microplasmin, TG-MV-007, which ...

ThromboGenics Completes Patient Enrolment of Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease

MIVI-TRUST Phase III Program With Microplasmin Recruits a Total of Over 640 patients Ahead of Schedule

21-Dec-2009 - ThromboGenics NV announced that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease. The trial TG-MV-007, which recruited patients both inEuropeandthe United States, has completed enrolment of over 320 patients across ...

ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-related Macular Degeneration (AMD)

11-Dec-2009 - ThromboGenics NV announced that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD). Abnormalities in the vitreomacular interface (the interface of the vitreous and macula) have been implicated in wet AMD, and recent ...

ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema

06-Oct-2009 - ThromboGenics NV announced results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME). The data from this trial were presented at the ASRS (American Society of Retina Specialists) Conference in New York by Professor Peter ...

ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema

09-Mar-2009 - ThromboGenics NV announced that it has completed patient enrolment for a Phase II trial of microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME). This trial is designed as the initial step in evaluating the utility of microplasmin in patients with ...

ThromboGenics Begins Phase III Program with Microplasmin for the Non-surgical Treatment of Back of the Eye Disease

ThromboGenics’ lead product to be studied in the treatment of vitreomacular adhesion in the US and Europe

12-Jan-2009 - ThromboGenics NV announced that it has started the Phase III clinical program of microplasmin for the non-surgical treatment of back of the eye disease, the final step in the clinical development of this potential new therapy. This program involves two clinical trials, taking place in the United ...

ThromboGenics Announces Promising Six Month Follow-Up Results from its Phase IIb Trial of Microplasmin (MIVI III)

Results continue to support microplasmin’s potential to make a major contribution to the treatment of back of the eye disease

17-Nov-2008 - ThromboGenics NV announced promising six month follow-up results from its Phase IIb MIVI III trial, which was designed to evaluate the safety and efficacy of microplasmin in vitrectomy. The results were presented at the American Academy of Ophthalmology in Atlanta, USA, by Dr. Kirk Packo, ...